Effectiveness of Superior Hypogastric Plexus Block for Faster Recovery After Laparoscopic Surgery for Colorectal Cancer

What this Trial Is About

Researchers are evaluating the effectiveness of a superior hypogastric plexus block SHPB to improve early recovery quality after laparoscopic colorectal cancer surgery. This single-center, randomized, double-blind, placebo-controlled trial will enroll 170 patients to compare SHPB with a placebo block. The study aims to clarify the role of SHPB within the Enhanced Recovery After Surgery ERAS strategy for this type of surgery. Participants will be randomly assigned to receive either a SHPB containing 20 mL of 0.75% ropivacaine hydrochloride or a placebo block with 20 mL of 0.9% normal saline after pneumoperitoneum is established during surgery. The injection is performed by tenting the presacral peritoneum and using a laparoscopic needle-tip syringe for precise delivery. This intervention occurs during laparoscopic colorectal cancer surgery, with patients monitored closely afterward. During the study, researchers will assess the quality of recovery using the 15-item Quality of Recovery QoR-15 score at 24 hours after surgery. They will also evaluate pain scores at rest and during movement, morphine use, time to first bowel movement, incidence of postoperative ileus, length of hospital stay, and inflammation markers such as interleukin-6 and C-reactive protein. Secondary measures include pain inventories and questionnaires up to 90 days after surgery. Safety and recovery progress will be tracked throughout the hospital stay and up to three months post-surgery.

Superior HypogastrIc plExus bLock During Laparoscopic Colorectal Cancer Surgery